SAMAR MAHMOOD: Open Payments
NPI 1669545943 · DEKALB, IL. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,723 in 64 payments from 12 companies in 2025. Trend: 2023 $1,275 · 2024 $840 · 2025 $1,723
Food & beverage: $1,723
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 24 | $635 |
| Neurocrine BioSciences, Inc. | 8 | $305 |
| Vanda Pharmaceuticals Inc. | 3 | $202 |
| E.R. Squibb & Sons, L.L.C. | 11 | $161 |
| Teva Pharmaceuticals USA, Inc. | 4 | $85 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 3 | $82 |
| Otsuka America Pharmaceutical, Inc. | 2 | $63 |
| Supernus Pharmaceuticals, Inc. | 3 | $54 |
| Alkermes, Inc. | 2 | $50 |
| Lundbeck LLC | 2 | $50 |
Products named: VRAYLAR, INGREZZA, FANAPT, COBENFY, REXULTI, CAPLYTA, Qelbree, UZEDY.
Industry payments across IL — which companies pay providers there.
